413 related articles for article (PubMed ID: 15661634)
1. Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.
Heidbreder CA; Hagan JJ
Curr Opin Pharmacol; 2005 Feb; 5(1):107-18. PubMed ID: 15661634
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy of addictions.
Kreek MJ; LaForge KS; Butelman E
Nat Rev Drug Discov; 2002 Sep; 1(9):710-26. PubMed ID: 12209151
[TBL] [Abstract][Full Text] [Related]
3. Vivitrex (Alkermes/Cephalon).
Heading CE
Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapies for adolescent substance use disorders.
Simkin DR; Grenoble S
Child Adolesc Psychiatr Clin N Am; 2010 Jul; 19(3):591-608. PubMed ID: 20682223
[TBL] [Abstract][Full Text] [Related]
5. [Limited role of naltrexone in the treatment of opiate addiction].
van Brussel GH
Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
[TBL] [Abstract][Full Text] [Related]
6. Clinical uses of naltrexone: a review of the evidence.
Modesto-Lowe V; Van Kirk J
Exp Clin Psychopharmacol; 2002 Aug; 10(3):213-27. PubMed ID: 12233982
[TBL] [Abstract][Full Text] [Related]
7. Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
O'Brien CP
Am J Psychiatry; 2005 Aug; 162(8):1423-31. PubMed ID: 16055763
[TBL] [Abstract][Full Text] [Related]
8. New horizons for therapeutics in drug and alcohol abuse.
Jupp B; Lawrence AJ
Pharmacol Ther; 2010 Jan; 125(1):138-68. PubMed ID: 19917308
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic management of relapse prevention in addictive disorders.
Sofuoglu M; Kosten TR
Psychiatr Clin North Am; 2004 Dec; 27(4):627-48. PubMed ID: 15550284
[TBL] [Abstract][Full Text] [Related]
10. Addiction pharmacotherapy 2000: new options, new challenges.
Rawson RA; McCann MJ; Hasson AJ; Ling W
J Psychoactive Drugs; 2000; 32(4):371-8. PubMed ID: 11210198
[TBL] [Abstract][Full Text] [Related]
11. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
McCann DJ
Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for Substance Use Disorders.
Klein JW
Med Clin North Am; 2016 Jul; 100(4):891-910. PubMed ID: 27235620
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
Haile CN; Kosten TA; Kosten TR
Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
[TBL] [Abstract][Full Text] [Related]
14. Naltrexone in patients with bipolar disorder and alcohol dependence.
Brown ES; Beard L; Dobbs L; Rush AJ
Depress Anxiety; 2006; 23(8):492-5. PubMed ID: 16841344
[TBL] [Abstract][Full Text] [Related]
15. Behavioral health issue brief: pharmacotherapy treatment of alcoholism and drug addiction: overview and bibliography: year end report-2002.
Colker AC
Issue Brief Health Policy Track Serv; 2002 Dec; ():1-6. PubMed ID: 12875273
[No Abstract] [Full Text] [Related]
16. Medications for substance use disorders.
Douaihy AB; Kelly TM; Sullivan C
Soc Work Public Health; 2013; 28(3-4):264-78. PubMed ID: 23731419
[TBL] [Abstract][Full Text] [Related]
17. Alcohol abuse and alcoholism: an overview.
Volpicelli JR
J Clin Psychiatry; 2001; 62 Suppl 20():4-10. PubMed ID: 11584874
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based pharmacological treatment of substance use disorders and pathological gambling.
van den Brink W
Curr Drug Abuse Rev; 2012 Mar; 5(1):3-31. PubMed ID: 22126708
[TBL] [Abstract][Full Text] [Related]
19. The role of the endogenous cannabinoid system in drug addiction.
Parolaro D; Rubino T
Drug News Perspect; 2008 Apr; 21(3):149-57. PubMed ID: 18560613
[TBL] [Abstract][Full Text] [Related]
20. [Naltrexone in the therapeutic relation in cases of opioid abuse and dependence].
Liffredo C; Gallino G
Minerva Med; 1993 Dec; 84(12):687-92. PubMed ID: 8127459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
